|14.11||-0.1800||-1.26%||Vol 463.07K||1Y Perf -15.64%|
|Jun 15th, 2021 16:00 DELAYED|
|- -||- -%|
|Target Price||25.00||Analyst Rating||Strong Buy 1.00|
|Potential %||77.18||Finscreener Ranking||★+ 43.98|
|Insiders Trans % 3/6/12 mo.||-/-82/-94||Value Ranking||★ 40.01|
|Insiders Value % 3/6/12 mo.||-79/-97/-99||Growth Ranking||★ 38.28|
|Insiders Shares Cnt. % 3/6/12 mo.||-79/-97/-99||Income Ranking||— -|
|Market Cap||1.07B||Earnings Rating||Strong Sell|
|Price Range Ratio 52W %||12.98||Earnings Date||5th Aug 2021|
Today's Price Range
5 Year PE Ratio Range
|Earnings History||Estimate||Reported||Surprise %|
|Q01 2021||0.09||-2.37||-2 733.33|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||5th Aug 2021|
|Estimated EPS Next Report||-0.18|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||659.00K|
|Avg. Monthly Volume||805.69K|
|Avg. Quarterly Volume||883.72K|
Coherus BioSciences Inc. (NASDAQ: CHRS) stock closed at 14.11 per share at the end of the most recent trading day (a -1.26% change compared to the prior day closing price) with a volume of 465.48K shares and market capitalization of 1.07B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 317 people. Coherus BioSciences Inc. CEO is Dennis M. Lanfear.
The one-year performance of Coherus BioSciences Inc. stock is -15.64%, while year-to-date (YTD) performance is -18.81%. CHRS stock has a five-year performance of -11.87%. Its 52-week range is between 12.9 and 22.22, which gives CHRS stock a 52-week price range ratio of 12.98%
Coherus BioSciences Inc. currently has a PE ratio of -11.70, a price-to-book (PB) ratio of 8.60, a price-to-sale (PS) ratio of 2.48, a price to cashflow ratio of 8.50, a PEG ratio of 2.32, a ROA of -12.82%, a ROC of -12.53% and a ROE of -51.72%. The company’s profit margin is -18.39%, its EBITDA margin is -10.90%, and its revenue ttm is $442.68 Million , which makes it $5.84 revenue per share.
Of the last four earnings reports from Coherus BioSciences Inc., there were 1 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $-0.18 for the next earnings report. Coherus BioSciences Inc.’s next earnings report date is 05th Aug 2021.
The consensus rating of Wall Street analysts for Coherus BioSciences Inc. is Strong Buy (1), with a target price of $25, which is +77.18% compared to the current price. The earnings rating for Coherus BioSciences Inc. stock is Strong Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Coherus BioSciences Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Coherus BioSciences Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 10.71, ATR14 : 0.56, CCI20 : 118.19, Chaikin Money Flow : -0.14, MACD : -0.06, Money Flow Index : 75.37, ROC : 7.14, RSI : 53.84, STOCH (14,3) : 68.36, STOCH RSI : 0.54, UO : 53.11, Williams %R : -31.64), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Coherus BioSciences Inc. in the last 12-months were: Dennis M. Lanfear (Option Excercise at a value of $138 232), Dennis M. Lanfear (Sold 31 054 shares of value $421 229 ), Jean-Frederic Viret (Option Excercise at a value of $496 640), Jean-Frederic Viret (Sold 61 685 shares of value $1 231 881 ), Mary T. Szela (Option Excercise at a value of $569 800), Mary T. Szela (Sold 109 994 shares of value $1 933 519 ), Mats Wahlstrom (Sold 400 000 shares of value $6 860 040 ), McDavid Stilwell (Buy at a value of $49 668), Vincent R. Anicetti (Option Excercise at a value of $2 243 716), Vincent R. Anicetti (Sold 195 171 shares of value $3 527 654 ), Vladimir Vexler (Option Excercise at a value of $919 908), Vladimir Vexler (Sold 181 378 shares of value $3 077 412 )
Copyright © 2016-2021 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
This could take some time, please wait.